Hosted live on World Heart Day 2021, this clinical webinar explores the latest evidence and controversies in BP management. Chaired by Prof. Garry Jennings, the expert discussion unpacks the latest clinical controversies in BP management including targets, resistant hypertension, and new digital technology for BP monitoring.
Duration:Â 1 hour
Year recorded:Â 2021
Topics covered:
Controversies in BP targets and implications for practice post SPRINT trial
Latest advice for the diagnosis and management of resistant hypertension
Latest advice on out-of-office blood pressure monitoring
Digital health tools on the horizon for CVD prevention and monitoring
Applying new evidence to clinical practice to promote structured CVD prevention strategies
Further reading and resources:
Executive Director and Chief Scientific Officer at the Research Institute of McGill University Health Centre, Montreal, Canada
Dobney Chair in Clinical Research at The University of Western Australia and President of High Blood Pressure Research Council of Australia
Deputy Director and Head of the Blood Pressure Research Group at the Menzies Institute for Medical Research, University of Tasmania
GP and Executive Dean of the Faculty of Health Sciences and Medicine at Bond University
This event was hosted in partnership with the World Heart Federation and the High Blood Pressure Research Council of Australia.Â
The activity was funded by the Commonwealth Department of Health, as part of the Public Health and Chronic Disease program.
Clinical information for diagnosis and management of hypertension.
In recent decades, the management of modifiable risk factors, such as dyslipidaemia, hypertension and hyperglycaemia has undergone significant advancement.2 New and more aggressive pharmacotherapy regimes have driven treatment targets to levels not previously achievable and led to improvements in cardiovascular outcomes.
Dr Chengxue Helena Qin, Monash University - 2019 Vanguard Grant
Last updated12 October 2021